Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof

Details for Australian Patent Application No. 2008287335 (hide)

Owner Ludwig Institute for Cancer Research

Inventors Scott, Andrew Mark; Johns, Terrance Grant; Burgess, Antony Wilks; Old, Llyod J.

Agent Spruson & Ferguson

Pub. Number AU-A-2008287335

PCT Pub. Number WO2009/023265

Priority 60/964,692 14.08.07 US

Filing date 14 August 2008

Wipo publication date 19 February 2009

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

18 March 2010 PCT application entered the National Phase

  PCT publication WO2009/023265 Priority application(s): WO2009/023265

24 June 2010 Amendment Made

  The nature of the amendment is: Delete the co-inventor Burgess, Antony Wilks; Add co-inventor Stockert, Elizabeth

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008287339-4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-B[1, 4] diazepin2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases PLK1 to PLK4 for the treatment of proliferative diseases

2008287331-Voice enabled telnet interface